



Innovation at RI and Project Level

II RICH Symposium
"Fostering the Innovation Potential of Research Infrastructures"
May 8th, 2017


Anton Ussi
Operations & Finance Director
EATRIS ERIC
Innovation WP Leader, CORBEL Project
antonuss@eatris.eu

CORBEL - Shared Services for Life Science



This project receives funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 654248.

For Access, Data, ELSI, Innovation



“By harmonising user access, unifying data management, creating common ethical and legal services, and offering joint innovation support CORBEL will establish and support a new model for biological and medical research in Europe.”

<http://www.corbel-project.eu>

WP8 - fostering RI innovation potential

- Real time partnering & collaboration advice for RIs - open daily
- Template documents, guidelines and assistance with collaboration and knowledge sharing;
- Access to specialist knowledge in relation to business development and legal, regulatory or ethical aspects;
- Hands on involvement by Innovation Office staff with real collaboration and negotiation cases

WP8 - fostering RI innovation potential


- Represent RIs at BIO partnering convention (3000+ pharma/biotech sector companies)
- Yearly joint industry/RI workshops on innovation, knowledge sharing

Please join us at the High Level Meeting - Innovation by Open Access, Brussels June 20th, 2017

<http://www.corbel-project.eu/innovation-by-open-access-meeting.html>

Translational research is

The process of turning observations in the laboratory, clinic and community into interventions



Mission

To support researchers in developing their biomedical discoveries for novel preventive, diagnostic or therapeutic products up to clinical proof of concept.

Supporting academia, funders, SME & biotech/pharma

What do we want to achieve

Reduce the cost of drugs; increase Europe's ability to compete

- Utilise cutting edge analytical tools from all relevant infrastructures
- Develop and validate more predictive in vitro and in vivo models
- Good access to high quality biosamples & related data
- Strong interaction between lab and clinic
- Take the pain out of public-private collaboration

**BRING TOGETHER EXPERTISE IN BIOLOGY, TECHNOLOGY & CLINIC
for faster, more efficient research and development**

€2 billion; 12 - 15 years for 1 new drug

We're not very good at biomedical innovation

- Academic focus on publications; papers don't heal patients
- Industry avoids early stage risk, leaving large translational gap
- Translational research is expensive, unsexy, requires team science approach
- Hugely fragmented field leads to lack of standards - reproducibility

IF WE WANT TO MAKES MEDICINES BETTER AND CHEAPER, ALL SECTORS HAVE TO MAKE FUNDAMENTAL CHANGES

What can we do?

Collaborate with peers and across sectors

- Invest in developing standards and quality systems
 - EATRIS initiatives include HTS ring testing, Zr-89 accreditation, FDA SEQC-2...
- Move from arms-length funding to investing in patient outcomes
 - EATRIS Inside; ECaDE early cancer detection
- Combine resources to validate tools for better R&D
 - EATRIS-GSK immune inflammation imaging hub

TRANSLATIONAL MEDICINE '17
Enhancing Predictivity

About Programme Speakers Workshops Abstract Accommodation REGISTER

ENHANCING PREDICTIVITY IN MEDICINES DEVELOPMENT

September 24-26, 2017 — Prague, Czech Republic

REGISTER

[Submit your abstracts](#)

Powered by **eatris**

TRANSLATIONAL MEDICINE'17, September 24 – 26, Prague